PhaseBio, Eyegate raise venture funding

Research Triangle Park, NC-based PhaseBio Pharmaceuticals has raised $25 million in a Series B financing round. New investors New Enterprise Associates and OSI Investment Management, a subsidiary of OSI Pharmaceuticals, led the round. The protein engineering company boasts a platform called Elastin-Like Polypeptide (ELP) technology, which boosts the pharmacology and delivery of therapeutics.

"The financing provides us funding that will allow us to build our pipeline of ELP-based therapeutics including advancing our lead programs through Phase 1/2 proof-of-concept studies in patients," Christopher Prior, CEO of PhaseBio Pharmaceuticals, says in a statement.

- see the release from PhaseBio

ALSO: Waltham, MA's EyeGate Pharma has landed $22.6 million in Series D venture financing. Eyegate gained access to $11 million of that in December 2009; the remainder will be held in reserve for future use. The funding will be used to bankroll clinical trials of EGP-437 for dry eye syndrome. A Phase III study of the drug is planned for the first half of this year. EyeGate release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.